Systematic review evaluates Alzheimer’s risk reduction in type 2 diabetes using GLP-1RAs or SGLT2i, suggesting potential benefits.
To evaluate whether the use of GLP-1 receptor agonists (GLP-1RAs) and SGLT2 inhibitors (SGLT2i) reduces the risk of Alzheimer’s disease (AD) and dementia in patients with type 2 diabetes (DM2).
No takes yet. Share an insight, caveat, or question.
Silva et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: